Intravitreal Bevacizumab for Inflammatory Neovascular Membranes
May 29, 2024 updated by: Asociación para Evitar la Ceguera en México
Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation
Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation.
We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.
Study Overview
Status
Withdrawn
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Distrito Federal
-
Mexico, Distrito Federal, Mexico, 04030
- Asociación Para Evitar la Ceguera en México
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Clinical Diagnose
- Patient Consent
- Chronic stage of inflammation
Exclusion Criteria:
- only eye
- age lower than 30 yo.
- Systemic condition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Best corrected visual acuity
|
|
Retinal thickness by OCT
|
|
Leakage in Fluorescein angiogram
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: LuzElena Concha-Del Rio, MD, Asociación Para Evitar la Ceguera en México
- Principal Investigator: Veronica Kon-Jara, MD, Asociación Para Evitar la Ceguera en México
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2006
Primary Completion (Actual)
December 1, 2006
Study Completion (Actual)
December 1, 2006
Study Registration Dates
First Submitted
December 1, 2006
First Submitted That Met QC Criteria
December 1, 2006
First Posted (Estimated)
December 4, 2006
Study Record Updates
Last Update Posted (Actual)
May 30, 2024
Last Update Submitted That Met QC Criteria
May 29, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Immune System Diseases
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Eye Diseases
- Panuveitis
- Uveitis
- Uveal Diseases
- Choroid Diseases
- Uveitis, Posterior
- Uveomeningoencephalitic Syndrome
- White Dot Syndromes
- Choroiditis
- Multifocal Choroiditis
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- APEC-0025
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.